Maintenance therapy for angioimmunoblastic T-cell lymphoma includes maintenance chemotherapy and molecular targeted therapy. Angioimmunoblastic T-cell lymphoma, or angioimmunoblastic T-cell lymphoma, is a subtype of non-Hodgkin’s lymphoma with highly aggressive disease and a poor prognosis. First-line treatments for this disease include combination chemotherapy, molecularly targeted therapy, and bone marrow transplantation. When the disease goes into remission after these treatments, further maintenance therapy is required. Maintenance chemotherapy and molecularly targeted therapy, such as the R-CHOP regimen, which combines rituximab molecularly targeted therapy with CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone) chemotherapy, are the mainstays of maintenance therapy in clinics. During maintenance therapy, the disease may recur or progress, and regular follow-up tests such as PET-CT, bone marrow aspiration and biopsy are required to assess the disease and thus guide clinical treatment.